Complex of Aldose Reductase with NADP+ and simaltaneously bound competetive inhibitors Fidarestat and IDD594. Concentration of Fidarestat in soaking solution exceeds concentration of IDD594.

Complex of Aldose Reductase with NADP+ and simaltaneously bound competetive inhibitors Fidarestat and IDD594. Concentration of Fidarestat in soaking solution exceeds concentration of IDD594. — Image 2 of 14

Complex of Aldose Reductase with NADP+ and simaltaneously bound competetive inhibitors Fidarestat and IDD594. Concentration of Fidarestat in soaking solution exceeds concentration of IDD594. — Image 3 of 14

Complex of Aldose Reductase with NADP+ and simaltaneously bound competetive inhibitors Fidarestat and IDD594. Concentration of Fidarestat in soaking solution exceeds concentration of IDD594. — Image 4 of 14

Complex of Aldose Reductase with NADP+ and simaltaneously bound competetive inhibitors Fidarestat and IDD594. Concentration of Fidarestat in soaking solution exceeds concentration of IDD594. — Image 5 of 14

Complex of Aldose Reductase with NADP+ and simaltaneously bound competetive inhibitors Fidarestat and IDD594. Concentration of Fidarestat in soaking solution exceeds concentration of IDD594. — Image 6 of 14

Complex of Aldose Reductase with NADP+ and simaltaneously bound competetive inhibitors Fidarestat and IDD594. Concentration of Fidarestat in soaking solution exceeds concentration of IDD594. — Image 7 of 14

Complex of Aldose Reductase with NADP+ and simaltaneously bound competetive inhibitors Fidarestat and IDD594. Concentration of Fidarestat in soaking solution exceeds concentration of IDD594. — Image 8 of 14

Complex of Aldose Reductase with NADP+ and simaltaneously bound competetive inhibitors Fidarestat and IDD594. Concentration of Fidarestat in soaking solution exceeds concentration of IDD594. — Image 9 of 14

Complex of Aldose Reductase with NADP+ and simaltaneously bound competetive inhibitors Fidarestat and IDD594. Concentration of Fidarestat in soaking solution exceeds concentration of IDD594. — Image 10 of 14

Complex of Aldose Reductase with NADP+ and simaltaneously bound competetive inhibitors Fidarestat and IDD594. Concentration of Fidarestat in soaking solution exceeds concentration of IDD594. — Image 11 of 14

Complex of Aldose Reductase with NADP+ and simaltaneously bound competetive inhibitors Fidarestat and IDD594. Concentration of Fidarestat in soaking solution exceeds concentration of IDD594. — Image 12 of 14

Complex of Aldose Reductase with NADP+ and simaltaneously bound competetive inhibitors Fidarestat and IDD594. Concentration of Fidarestat in soaking solution exceeds concentration of IDD594. — Image 13 of 14

Complex of Aldose Reductase with NADP+ and simaltaneously bound competetive inhibitors Fidarestat and IDD594. Concentration of Fidarestat in soaking solution exceeds concentration of IDD594. — Image 14 of 14

3D model · NIH 3D

Complex of Aldose Reductase with NADP+ and simaltaneously bound competetive inhibitors Fidarestat and IDD594. Concentration of Fidarestat in soaking solution exceeds concentration of IDD594.

Platform: NIH 3D
Price: Free
License: CC-BY; Print, modify and use commercially — credit the author.
Formats: WRLX3DSTLGLB

47 Downloads
79 Views

Author:laurelleber

Published 2023-07-18

Description

PDB Classifiation: OXIDOREDUCTASE

Tags

oxidoreductase nadp idd594 fidarestat escherichia coli amore hkl-2000 shelxl-97

More like this

Similar models

Structural Analysis of a Holo Enzyme Complex of Mouse Dihydrofolate Reductase with NADPH and a Ternary Complex with the Potent and Selective Inhibitor 2.4-Diamino-6-(-2'-hydroxydibenz[b,f]azepin-5-yl)methylpteridine

Structural Analysis of a Holo Enzyme Complex of Mouse Dihydrofolate Reductase with NADPH and a Ternary Complex with the Potent and Selective Inhibitor 2.4-Diamino-6-(-2'-hydroxydibenz[b,f]azepin-5-yl)methylpteridine

NIH 3D · lastsnare

carbonic anhydrase II in complex with furosemide as sulfonamide inhibitor

carbonic anhydrase II in complex with furosemide as sulfonamide inhibitor

NIH 3D · laurelleber

Wild Type HIV-1 Protease with potent Antiviral inhibitor GRL-0255A

Wild Type HIV-1 Protease with potent Antiviral inhibitor GRL-0255A

NIH 3D · TAN WOON YAN

Crystal structure analysis of HIV-1 protease mutant V82A with a inhibitor saquinavir

Crystal structure analysis of HIV-1 protease mutant V82A with a inhibitor saquinavir

NIH 3D · john_h413

Crystal structure of human cytosolic NADP(+)-dependent isocitrate dehydrogenase in complex NADP

Crystal structure of human cytosolic NADP(+)-dependent isocitrate dehydrogenase in complex NADP

NIH 3D · nevitdilmen

structure of DHFR with bound DAP, p-ABG and NADP

structure of DHFR with bound DAP, p-ABG and NADP

NIH 3D · Meghan McCarthy

Free $Crystal Polymorphism of Protein GB1 Examined by Solid-state NMR and X-ray Diffraction$

Crystal Polymorphism of Protein GB1 Examined by Solid-state NMR and X-ray Diffraction

NIH 3D · horne

Crystal Structure Analysis of human IDH1 mutants in complex with NADP+ and Ca2+/alpha-Ketoglutarate

Crystal Structure Analysis of human IDH1 mutants in complex with NADP+ and Ca2+/alpha-Ketoglutarate

NIH 3D · nevitdilmen

Crystal structure of iridoid synthase in complex with NADP+ and 8-oxogeranial at 2.65-angstrom resolution

Crystal structure of iridoid synthase in complex with NADP+ and 8-oxogeranial at 2.65-angstrom resolution

NIH 3D · Vignesh

Crystal structure analysis of HIV-1 protease with a substrate analog P6-PR

Crystal structure analysis of HIV-1 protease with a substrate analog P6-PR

NIH 3D · chris@printhuman.org

Crystal structure analysis of HIV-1 protease with a substrate analog P1-P6

Crystal structure analysis of HIV-1 protease with a substrate analog P1-P6

NIH 3D · chris@printhuman.org

High throughput screening and x-ray crystallography assisted evaluation of small molecule scaffolds for CYP51 inhibitors

High throughput screening and x-ray crystallography assisted evaluation of small molecule scaffolds for CYP51 inhibitors

NIH 3D · sbi3clp

Names are used only to indicate the source of a result. Polyzon is not affiliated with the listed sites.